This playbook explores the risks and complexities inherent to tech transfer in viral vector manufacturing and offers a roadmap for overcoming them. The rising demand for viral vectors is outpacing drug developers’ in-house production capabilities, making tech transfer a prerequisite for scale-up in many programs. Viral vector tech transfer is inherently complex and resource intensive, with each program behaving like a new product, frequently requiring significant development, optimization, and validation. But there are strategies for streamlining and derisking the process. This playbook explores why tech transfer in viral vector manufacturing is complex and full of risks and offers a roadmap for overcoming these challenges. An exceptional CDMO partner can help. Highlights include: Why it can be a challenge to preserve process performance in viral vector tech transfer and what a successful program looks like. The value of a gap analysis and facility fit assessment — and the most common issues it uncovers. Four attributes to look for in a viral vector CDMO partnership to achieve seamless tech transfer.
